Novartis and Ablynx are collaborating to discover and develop therapeutic Nanobodies for a range of disease areas, against a number of targets that are difficult to address with conventional antibodies and their fragments. The alliance was entered into in December 2005, and extended in December 2007 for a further year.
Edwin Moses, CEO and chairman of Ablynx, said: “We are pleased to see this first Nanobody program from our collaboration with Novartis advancing to the next stage and to make progress in what is an important alliance for Ablynx.”